Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
Background and Aims: Anti-tumor necrosis factor mAb (i.e., adalimumab, ADA) is currently used in the treatment of patients with Crohn’s disease (CD). However, its regulation on fecal microbiota is still not fully understood.Methods: A retrospective analysis was conducted on 115 patients with CD who...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2022-08-01
|
| Collection: | Frontiers in Pharmacology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fphar.2022.913720/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|